EP Patent

EP1619251A1 — A mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy

Assigned to Universiteit Leiden · Expires 2006-01-25 · 20y expired

What this patent protects

The present invention relates to novel nucleic acid and protein molecules and their use in cancer therapy and diagnosis.

USPTO Abstract

The present invention relates to novel nucleic acid and protein molecules and their use in cancer therapy and diagnosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP1619251A1
Jurisdiction
EP
Classification
—
Expires
2006-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Universiteit Leiden
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.